Provided are a compound as shown in formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof as an androgen receptor (AR) antagonist, preferably for treating androgen receptor-mediated alopecia.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present disclosure relates to a IRAK4 degradation agent compound, and specifically provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features described in the present application. The application also discloses a pharmaceutical composition comprising the compound represented by formula (I) or a pharmaceutically acceptable salt of the composition, and a pharmaceutical use of the compound or the pharmaceutically acceptable salt thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Provided are a degradation agent compound targeting IRAK4 having a structure of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition can be used for preventing or treating IRAK4-mediated diseases, including but not limited to tumors, inflammatory diseases, neurodegenerative diseases or autoimmune diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 37/00 - Drugs for immunological or allergic disorders
Provided are compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and the use thereof as androgen receptor (AR) antagonists in the treatment or prevention of androgen receptor-mediated diseases, preferably for the treatment of androgen receptor-mediated alopecia, such as androgenetic alopecia.
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07C 255/60 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
Provided are a compound represented by formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and the use thereof acting as an androgen receptor (AR) antagonist. The compound is preferably used for the treatment of androgen receptor-mediated alopecia.
A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the treatment of tumors, inflammatory diseases or autoimmune diseases.
A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the treatment of tumors, inflammatory diseases or autoimmune diseases.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61P 5/46 - Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
7.
USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKE
Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition includes edaravone and dexborneol, and the patient has a history of hypertension.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides a compound and use thereof, particularly a JWA gene agonist and use thereof in preventing or treating radiation damage. The compound, by means of activating JWA gene expression, enhances the DNA repair capacity of cells, and has a good elimination capacity for highly active oxygen species generated by X-ray radiation. The compound can also effectively inhibit cell apoptosis caused by radiation to reduce the damage, and further reduce the generation of free radicals to reduce the probability of radiation damage.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A stable pharmaceutical composition contains active ingredients of edaravone and dextrocamphol can control the content of unique impurity SCR-756 and impurity SCR-757 thereof.
C07D 231/24 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
Disclosed are a pyrrolidine compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use of the pharmaceutical composition as a selective estrogen receptor degrader (SERD) in the prevention or treatment of estrogen receptor-related diseases.
Disclosed are a pyrrolidine compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use of the pharmaceutical composition as a selective estrogen receptor degrader (SERD) in the prevention or treatment of estrogen receptor-related diseases.
nn or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising the conjugate, and use thereof in treating autoimmune diseases or inflammatory diseases.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids
12.
PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF
Provided are a pharmaceutical composition of an aquaporin inhibitor and a preparation method thereof. The pharmaceutical composition comprises 2-((3,5-bis (trifluoromethyl) phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of the aquaporin inhibitor and the preparation method thereof have the following advantages: the process is simple, has strong operability, and is conducive to industrial production, and the product has good stability, and obviously less content of degradable impurities, which ensures the effectiveness of the medicine.
The present invention provides a pharmaceutical composition or a combined pharmaceutical composition of a PRMT5 inhibitor compound selected from a compound I and a pharmaceutically acceptable salt thereof and at least one other anti-cancer therapeutic agent, and a use of the PRMT5 inhibitor compound and the at least one other anti-cancer therapeutic agent in preparation of drugs for treating tumor diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention provides a pharmaceutically acceptable salt of a compound as a PRMT5 inhibitor, a crystal form of the pharmaceutically acceptable salt, a preparation method therefor, a pharmaceutical composition comprising the pharmaceutically acceptable salt or the crystal form thereof, and the use of the pharmaceutically acceptable salt or the pharmaceutical composition comprising the pharmaceutically acceptable salt in the preparation of a drug for preventing or treating related pharmacological conditions.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
The present invention relates to an antibody against a B-cell maturation antigen (BCMA) and the use thereof. Specifically, disclosed are an antibody specifically binding to BCMA or an antigen-binding fragment thereof, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in the preparation of a pharmaceutical composition for treating diseases, for example, for treating tumors. The present invention has important significance for the development of a therapeutic BCMA antibody drug and a detection reagent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An antibody, or an antigen-binding fragment of same, specifically binding to a BCMA, a nucleic acid encoding same, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in treating a disease, for example, the use thereof in treating a tumour.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to a proteolysis-targeting chimera (PROTAC) molecule, further relates to a BRM selective degradation agent compound, and specifically provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features of the present application. The present application also describes a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound or the pharmaceutically acceptable salt thereof in medicine.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A multi-specific antibody and a pharmaceutical use thereof. The multi-specific antibody comprises at least three parts: (A) a target antigen binding part, (B) a half-life extending part, and (C) a T cell engaging part. By binding to two or more targets at the same time, the multi-specific antibody can simultaneously exert multiple functions, so as to prevent and/or treat proliferative diseases.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed is an IL-15 mutant fusion protein preparation. Specifically, provided is an IL-15 mutant fusion protein pharmaceutical composition. The composition comprises an IL-15 mutant fusion protein, a buffer solution, a protein stabilizer and a surfactant. The pharmaceutical composition can maintain the stability of the IL-15 mutant fusion protein in the long-term storage and transportation process of the product, and thus, the stability, safety and effectiveness of the drug are ensured.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A pharmaceutically acceptable salt of the compound of formula (I), a crystal thereof, a preparation method therefor, and a use thereof. The pharmaceutically acceptable salt is selected from sulfate, phosphate, benzoate, succinate, adipate, fumarate, L-malate, and citrate, preferably benzoate, succinate, and adipate.
A drug combination comprising a compound represented by formula (K) as a selective estrogen receptor downregulator (SERD) or a pharmaceutically acceptable salt thereof and a CDK4/6 inhibitor, a combined product or pharmaceutical composition containing the drug combination, and an application thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided is a high affinity SIRPa polypeptide, comprising at least one amino acid change relative to a wild-type protein; and having an increased affinity for CD47 relative to the wild-type protein. Also provided are a nucleic acid molecule encoding the SIRPa polypeptide and a vector expressing the polypeptide. Further provided are a pharmaceutical composition and a method for treating tumors expressing CD47.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
Disclosed is an antibody or an antigen-binding fragment thereof capable of specifically binding to MUC17. The antibody or the antigen-binding fragment thereof can specifically bind to MUC17 with high affinity, and can be used as a drug for treating malignant gastrointestinal tumors.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided are a class of heterocyclic compounds as an SOS1 inhibitor, specifically disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and the salt thereof, and a use of the compound and the salt thereof in the preparation of drugs for treating cancers.
Disclosed is the use of a docetaxel polymer micelle in the preparation of a drug for preventing or treating malignant hydrothorax and ascites. The docetaxel polymer micelle is used for treating malignant hydrothorax and ascites, which can significantly prolong survival, improve the treatment effect of hydrothorax and ascites, increase the plasma exposure amount of the drug, and reduce the secretion of VEGF.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/19 - Particulate form, e.g. powders lyophilised
Provided are an anti-human CD3 antibody and the use thereof. Specifically, provided are an antibody specifically binding to human CD3 or an antigen binding fragment thereof, a multi-specific antigen binding molecule, an isolated nucleic acid molecule, a vector, a cell and an immune effector cell thereof, a method for preparing the antibody or the antigen binding fragment thereof, the multi-specific antigen binding molecule and the immune effector cell, a pharmaceutical composition, the pharmaceutical use and a method for treating diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A purification method for an amphiphilic block copolymer, a purified amphiphilic block copolymer, and a pharmaceutical composition comprising the amphiphilic block copolymer. The purification method of the amphiphilic block copolymer comprises: (1) providing a solution comprising the amphiphilic block copolymer in an organic solvent; (2) adding activated carbon to the solution of step (1); and (3) filtering to remove the activated carbon, obtaining the amphiphilic block copolymer. The provided method can effectively remove metallic tin ion content from the amphiphilic block copolymer.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
28.
HYDROPHOBIC DRUG POLYMER MICELLE AND PREPARATION METHOD THEREFOR
Provided is a polyethylene glycol monomethyl ether-polylactic acid block copolymer and a preparation method therefor. The polyethylene glycol monomethyl ether-polylactic acid block copolymer is a block copolymer formed by means of ring-opening polymerization of D,L-lactide and polyethylene glycol monomethyl ether, wherein the feed mass ratio of polyethylene glycol monomethyl ether to D,L-lactide is 1:1.05-1.25. Also provided is a hydrophobic drug polymer micelle lyophilized preparation. The lyophilized preparation contains a hydrophobic drug and the polyethylene glycol monomethyl ether-polylactic acid block copolymer. The hydrophobic drug polymer micelle lyophilized preparation has higher purity and redissolution stability, and is more suitable for clinical use.
Provided are a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the anti-tumor use thereof.
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing them, and their use as a selective androgen receptor degradation (SARD) agent and/or androgen receptor (AR) antagonist, particularly suited for preparing medications for the treatment or prevention of diseases brought about by androgen receptors.
C07C 233/01 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
The present disclosure relates to a CD16 antibody and an application thereof. Specifically, the present disclosure relates to an antibody or antigen-binding fragment specifically binding to CD16, an encoding nucleic acid, an expression vector and an expression cell therefor, a preparation method, a pharmaceutical composition, and a use of them in the treatment of diseases, for example, a use in the treatment of tumors. The invention has great significance for the development of a CD16 antibody therapeutic drug and a detection reagent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided is a bispecific antibody capable of specifically binding PVRIG and TIGIT. The bispecific antibody can regulate the function of immune cells and can be used as a drug to treat diseases, such as tumors, related to immune abnormalities.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A CD19 antibody and an application thereof, an antibody or antigen binding fragment specifically binding to human CD19, a multi-characteristic antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid molecule, a vector, a cell, a preparation method, a pharmaceutical composition, a pharmaceutical use, and a disease treatment method. The present invention has great significance for the development of drugs for treating CD19-related diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An antibody or antigen-binding fragment specifically binds to human programmed cell death ligand-1 (PD-L1). The antibody or antigen-binding fragment is able to enhance the function of T cells and upregulate a T cell-mediated immune response. The antibody or the antigen-binding fragment is useful for the treatment of diseases, e.g. tumor, associated with aberrant expression of PD-L1 and/or dysfunction of T cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a CD16 antibody and the use thereof. Specifically, disclosed are an antibody or an antigen-binding fragment specifically binding CD16, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof for treating diseases, such as the use thereof in the treatment of tumors. The CD16 antibody holds great significance for the development of a CD16 antibody therapeutic drug and a detection reagent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the treatment of tumors, inflammatory diseases or autoimmune diseases.
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61P 5/46 - Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
37.
ANTI-HUMAN MSLN HUMANIZED ANTIBODY AND USE THEREOF
The present invention relates to an anti-human MSLN humanized antibody and the use thereof. In particular, the present invention relates to an anti-human MSLN humanized antibody, a nucleic acid encoding same, a method for preparing an antibody, a pharmaceutical composition containing the antibody, and the related use of the pharmaceutical composition for treating a tumor.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A bifunctional fusion protein molecule containing an anti-human IL-17 antibody and TACI, comprising (a) an anti-human IL-17 antibody or antigen-binding fragment capable of blocking IL-17A/IL17RA binding, and (b) a TACI fusion protein or fragment capable of binding to BAFF/APRIL, and a preparation method therefor and an application thereof (for example, being used for the treatment of autoimmune diseases such as autoimmune encephalomyelitis).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
An anti-MSLN antibody, a preparation method therefor, and an application thereof. The MSLN antibody has a high affinity with MSLN protein, and is applicable to the preparation of drugs for the treatment of tumors, etc.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided in the present invention are a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, a preparation method therefor, and the use thereof as an HPK1 inhibitor.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
An antibody specifically binding to a GARP/TGFβ1 compound or an antigen-binding fragment thereof, a multispecific antigen-binding molecule and a chimeric antigen receptor containing same, an immune effector cell expressing the chimeric antigen receptor, and a pharmaceutical composition prepared from the antibody, a pharmaceutical use of the antibody, and a use of the antibody in treating a disease. The present invention further relates to an encoding nucleic acid, a vector containing the nucleic acid, a host cell containing the nucleic acid or vector, and a method for preparing and purifying the antibody.
Nanobodies specifically binding to human serum albumin (HSA) and applications thereof. The present invention specifically relates to alpaca and humanized nanobodies or antigen binding fragments thereof capable of binding to HSA, having good affinity with human, rat, monkey serum albumin, and having great significance in the treatment of cancer and autoimmune diseases.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
43.
NEW SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
An SOS1 inhibitor compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for treating cancers.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
Provided are a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and a preparation method therefor, and a use thereof as an HPK1 inhibitor.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Provided is a humanized antibody or antigen-binding fragment that specifically binds to GPC3. The antibody or antigen-binding fragment has high affinity with GPC3 protein, and can be used in the preparation of drugs for treating tumors and the like. Also provided are a nucleic acid molecule encoding the humanized GPC3 antibody or antigen-binding fragment, an expression vector, a host cell, and a method for preparing the antibody or antigen-binding fragment. Also provided are an immunoconjugate comprising same, a chimeric antigen receptor, an immunocompetent cell, a multispecific molecule, and a pharmaceutical composition. Also provided are a method for detecting GPC3, and a method for treating various GPC3-related disorders including hepatocellular carcinoma.
An anti-CD33 antibody and a preparation method therefor and an application thereof. The anti-CD33 antibody has high affinity with CD33 protein, and therefore, can be used for preparation of a drug for treating tumor and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an isolated monoclonal antibody specifically binding to glypican-3 (GPC3) with high affinity, a nucleic acid molecule encoding a GPC3 antibody, an expression vector, a host cell, a method for preparing a GPC3 antibody, and an immunoconjugate, chimeric antigen receptor, immunocompetent cell, multispecific molecule, and pharmaceutical composition comprising the GPC3 antibody. Further provided are a method for detecting GPC3, and a method for treating GPC3-related diseases comprising hepatocellular carcinoma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a series of compounds of an SOS1 inhibitor. Specifically disclosed are a compound of formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and the salt thereof, and an application of the compound and the salt thereof in preparation of drugs for treating cancers.
Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a compound shown in formula (I) as a CDK2/4/6 inhibitor, or a stereoisomer (such as an optical isomer) thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and an application thereof in the preparation of a drug for treating cancer.
CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein. Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases such as tumors and autoimmune diseases.
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to a CD3 humanized antibody and an application thereof, and disclosed are a humanized antibody or an antigen-binding fragment that specifically binds to a CD3ε subunit, a multi-specific antigen-binding molecule, a nucleic acid fragment, a carrier, a host cell, a preparation method, a pharmaceutical composition, a pharmaceutical use, and a treatment method for cancer or tumors, infectious diseases or autoimmune diseases. In addition, the present invention is extremely important for the development of CD3 antibody drugs and cell therapy drugs.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An antibody or antigen binding fragment that specifically binds to CD5, a polypeptide, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a preparation method, and use thereof in the treatment of diseases and in the detection of CD5, etc., which have important meanings for developing therapeutic drugs and CD5 detection reagents.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
An antibody or antigen-binding fragment specifically binding to HER2, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a kit, a preparation method, and an application thereof in treatment of tumors or cancers and detection of HER2, which is of great significance for the development of HER2 antibody therapeutic drugs and detection reagents.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are a GPC3 antibody and an application thereof, and specifically provided are an antibody or an antigen-binding fragment that specifically binds to GPC3, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, isolated nucleic acid fragments, a vector, a host cell, a corresponding preparation method, a pharmaceutical composition, a treatment method, a pharmaceutical use, a GPC3 detection method and a detection kit. The present disclosure is of great significance in the preparation of drugs for treating cancer or tumor.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
An EGFR nanobody, and a preparation method therefor and the use thereof. The EGFR nanobody has high affinity for a wild-type EGFR protein, and also recognizes the EGFRvIII protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A single domain antibody for mesothelin (MSLN), and a preparation method therefor and an application thereof. An MSLN antibody has high affinity to an MSLN protein, and therefore can be applied in the preparation of a drug treating tumors and the like.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided are an CD22 nano antibody, and a preparation method therefor and an application thereof. The CD22 nano antibody has high affinity with a CD22 protein, and can be used for preparing drugs for treating tumors, autoimmune diseases, etc.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a humanized CD19 antibody and the use thereof. Specifically, provided are an antibody- or antigen-binding fragment capable of binding to CD19, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a cell, a composition, a preparation method, a pharmaceutical use and a method for treating cancers and autoimmune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A glibenclamide pharmaceutical composition for nasal administration and a preparation method therefor. The glibenclamide pharmaceutical composition solves the technical problems of a low concentration of the drug in the brain and easily causing the side effect of severe hypoglycemia, significantly increases the solubility of the drug, achieves a higher concentration in the brain without increasing the risk of hypoglycemia, improves brain targeting, and facilitates better patient compliance.
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
An antibody binding to CD70 and an application thereof. Specifically, disclosed are an antibody or antigen-binding fragment capable of binding to CD70, a corresponding multispecific antigen-binding molecule, a chimeric antigen receptor and an immune effector cell thereof, a nucleic acid fragment, a vector, a cell, a composition, a preparation method, a pharmaceutical use, and a method for treatment of cancers or tumors, autoimmune diseases or viral infections, which have important significance for treatment of tumors, autoimmune diseases, viral infections and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A pharmaceutical composition of glyburide administered nasally and a preparation method therefor. The pharmaceutical composition solves the technical problems of a low drug concentration in the brain and a side effect of easily causing severe hypoglycemia, and significantly improves the solubility of drugs, achieving a higher concentration in the brain without increasing the risk of hypoglycemia, improving brain targeting ability, and having better compliance.
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
64.
PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF GLYBURIDE AND PREPARATION METHOD THEREFOR
The present invention relates to a pharmaceutical composition for the nasal administration of glyburide and a preparation method therefor, the glyburide pharmaceutical composition of the present invention solves the technical problems in which the drug concentration within the brain is relatively low and the side effect of severe hypoglycemia can easily occur. The pharmaceutical composition of the present invention significantly improves drug solubility, achieving a higher concentration within the brain without increasing the risk of hypoglycemia, improves brain targeting, and has better compliance.
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to a compound shown in general formula (A) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, a preparation method for the compound, and a use of the compound as an MAT2A inhibitor.
Provided are a pyrimidopyrrole compound as represented by formula (Ia) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and a preparation method therefor, and use thereof as a JAK3 and/or BTK inhibitor.
Provided are an IL-2 mutant and an application thereof. Specifically disclosed are the IL-2 mutant, a corresponding fusion protein, conjugate, nucleic acid fragment, carrier and host cell, a preparation method for the mutant or the fusion protein, the IL-2 mutant or the fusion protein prepared according to the method, a pharmaceutical composition, a pharmaceutical use, a disease treatment method, and a method for preferentially stimulating a regulatory T cell. Compared with wild-type IL-2, the IL-2 mutant increases the Tm value and improves the stability of an IL-2 protein; or compared with a wild type, the IL-2 mutant increases the yield, or changes the binding activity to an IL-2Rβγ compound.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A stable pharmaceutical composition, belonging to the technical field of medicine. The pharmaceutical composition having active ingredients of edaravone and dextrocamphol can surprisingly control the content of unique impurity SCR-756 and impurity SCR-757 thereof. The problems of impurities and product quality being difficult to control and the storage life being short, etc. are solved from the source.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
69.
PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF
Provided are a pharmaceutical composition of an aquaporin inhibitor and a preparation method thereof. The pharmaceutical composition comprises 2-((3,5-bis (trifluoromethyl) phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of the aquaporin inhibitor and the preparation method thereof have the following advantages: the process is simple, has strong operability, and is conducive to industrial production, and the product has good stability, and obviously less content of degradable impurities, which ensures the effectiveness of the medicine.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the prevention and treatment of cerebrovascular diseases; pharmaceutical and biological preparations for medical use, namely, for the prevention and treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of autoinflammatory diseases; pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of pain.
Provided is an antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, wherein the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune-related disorders, such as tumors. A polynucleotide encoding the antibody or antigen-binding fragment thereof and a pharmaceutical composition comprising the antibody or antigen binding fragment thereof are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition comprises edaravone and dexborneol, and the patient has a history of hypertension.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
Use of a composition in the preparation of a medicament for treating cerebral stroke in a patient. The composition comprises Edaravone and Dexborneol, and the patient has a heart disease history.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
74.
USE OF COMPOSITION IN TREATMENT OF CEREBRAL APOPLEXY
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
The present application describes tetrahydroisoquinoline compounds as PRMT5 inhibitors and pharmaceutically acceptable salts thereof. Said compounds have the structure of formula (I), and have substituents and structural features described in the present application. The present application also describes pharmaceutical compositions comprising the compounds of formula (I) or pharmaceutically acceptable salts thereof and use of the compounds of formula (I) or pharmaceutically acceptable salts thereof and the pharmaceutical composition comprising same in the preparation of medicaments for preventing or treating diseases mediated by PRMT5.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Provided are a compound represented by formula (I) or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition, and a preparation therefor, and use as an MAT2A inhibitor.
The present application provides a compound having estrogen receptor modulating activity or function, or a pharmaceutically acceptable salt thereof. The compound has the structure of formula (I) and has substituents and structural features as described in the present application. The present application further provides a pharmaceutical composition containing the compound of formula (I) or the pharmaceutically acceptable salt thereof, and use of the compound of formula (I) or the pharmaceutically acceptable salt thereof in preparing a drug for preventing or treating estrogen receptor-related diseases.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
Provided in the present invention are a new polyaryl compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof as an EGFR kinase inhibitor in the prevention or treatment of related diseases.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A brexpiprazole-containing pharmaceutical composition and a preparation method therefor. The pharmaceutical composition comprises brexpiprazole and one or more dispersants. The pharmaceutical composition has no obvious burst release phenomenon after administration, long effective time, stable plasma-drug concentration, small plasma-drug concentration fluctuation amplitude and fast onset of action speed, and the preparation process is simple and convenient to operate.
Provided are a human IL-15 molecule mutant and a fusion protein containing the IL-15 mutant and combined mutations, wherein the fusion protein can mediate the activation and amplification of immune cells and can be used for treating tumor diseases.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed are a pyrrolidine compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use of the pharmaceutical composition as a selective estrogen receptor degrader (SERD) in the prevention or treatment of estrogen receptor-related diseases.
Provided in the present invention are boron-containing compounds as represented by formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions including same, and an application of serving as a selective estrogen receptor degrader (SERD) in the prevention or treatment of a related illness.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
The present application describes a substituted aryl compound used as an RAD51 inhibitor and a pharmaceutically acceptable salt thereof. The compound has the structure as represented by Formula (I) and has the substituents and structural features as described in the present application. Furthermore, the present application describes a pharmaceutical composition containing the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof, and the use of the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof and the pharmaceutical composition containing same in the preparation of a drug for preventing or treating RAD51 mediated diseases.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 277/28 - Radicals substituted by nitrogen atoms
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
Provided in the present application is a pyrimido five-membered ring compound represented by formula (Ib) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and a preparation method therefor, and a use thereof as a JAK3 and/or BTK inhibitor.
The present application provides a pyrimido five-membered ring compound as represented by formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a preparation method therefor, and a use thereof as a JAK3 and/or BTK inhibitor.
A compound as represented by general formula (A) or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition and a preparation method therefor, and use thereof as an MAT2A inhibitor.
Provided is a compound represented by formula (A) or a pharmaceutically acceptable salt or pharmaceutical composition thereof. The present invention is used for effective treatment of TGF-β-mediated diseases or disorders, including but not limited to cancer, fibrotic diseases or inflammatory diseases and so on.
Disclosed is an antibody specifically binding to a human CD38 or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof can mediate tumor cell apoptosis, and can be used for treating tumor diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed are a fourth-generation (T790M/C797S mutation) EGFR kinase inhibitor and a medical use thereof, and specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has a good therapeutic effect on a disease caused by an abnormal mutation of EGFR Del19/T790M/C797S or L858R/T790M/C797S.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The present invention relates to an antibody or antigen-binding fragment specifically binding to human programmed cell death ligand-1 (PD-L1), the antibody or antigen-binding fragment being able to enhance the function of T cells and upregulate a T cell-mediated immune response; the invention also relates to use of the antibody or the antigen-binding fragment for the treatment of diseases, e.g. tumor, associated with aberrant expression of PD-L1 and/or dysfunction of T cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention discloses a tetrahydroisoquinoline spiro compound represented by formula (I) as a PRMT5 inhibitor, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in the treatment of PRMT5-mediated diseases, wherein A is a 5-14 membered spiro group optionally substituted by R6.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
An antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune abnormalities, such as tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a fourth generation (T790M/C797S mutation) EGFR kinase inhibitor and a medical use thereof, and specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound in the present invention has a good therapeutic effect on diseases caused by abnormal mutations of EGFR Del19/T790M/C797S and L858R/T790M/C797S.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Disclosed in the present invention is a method for the high-throughput construction of a monoclonal antibody expression vector and the application of said method in high-throughput antibody discovery, the method comprising the following steps: sorting antigen-specific single B cells into high-throughput reaction vessels, and implementing high-throughput reverse transcription; using the acquired reverse transcription reaction product as a template, respectively implementing PCR amplification of the heavy chain and light chain variable regions; and respectively recombining the heavy chain variable region clone fragments and light chain variable region clone fragments into an expression vector, the expression vector containing the suicide gene ccdB.
Provided is a pharmaceutical composition, which contains 3-methyl-1-phenyl-2-pyrazoline-5-one, 3-butyl-1 (3H)-isobenzofuranone and borneoll. The pharmaceutical composition can effectively reduce the dosage of drugs, thereby reducing the toxic and side effects of drugs and the burden of the liver due to drug metabolism, and enhancing the efficacy of drugs.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
96.
PYRIMIDOPYRAZOLE COMPOUNDS AS FOURTH GENERATION EGFR INHIBITORS
Disclosed are novel pyrimidopyrazole compounds as fourth generation (T790M/C797S mutation) EGFR kinase inhibitors and pharmaceutical use thereof, specifically disclosed are a compound represented by formula (I), a stereoisomer, a racemate, a tautomer, an isotope label, a nitrogen oxide or a pharmaceutically acceptable salt thereof. Said compounds have good efficacy in treating diseases caused by abnormal mutation of EGFR Del19/T790M/C797S and L858R/T790M/C797S.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Troches; medicines for human purposes; biochemical drug;
reagents (chemical -) for medical or veterinary purposes;
diagnostic preparations for medical purposes; active
pharmaceutical ingredients; pharmaceutical preparations for
injection; Chinese patent medicines; dietetic substances
adapted for medical use; dietetic foods adapted for medical
purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicated troches; Medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; [ Biochemicial ] * Biochemical * drug for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musculo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical purposes; Active pharmaceutical ingredients, namely, extracts of hops for pharmaceutical purposes, eucalyptus for pharmaceutical purposes, mint for pharmaceutical purposes, malt for pharmaceutical purposes, pepsins for pharmaceutical purposes,thymol for pharmaceutical purposes,turpentine for pharmaceutical purposes, flaxseed for pharmaceutical purposes, ferments for pharmaceutical purposes, cytostatics for pharmaceutical purposes, balms for pharmaceutical purposes, digestives for pharmaceutical purposes, iodine for pharmaceutical purposes, alcohol for pharmaceutical purposes, starch for pharmaceutical purposes; Pharmaceutical preparations for injection for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chinese patent medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, and, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes
99.
AZACITIDINE DISACCHARIDE IMPURITY, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to an azacitidine disaccharide impurity, a preparation method therefor and use thereof. A compound of formula III is obtained by reacting a compound represented by formula IV as a start raw material with a tetraacetyl ribose under the catalysis of a Lewis acid, and the compound of formula III is hydrolyzed to obtain a compound of formula II. The compound of formula II prepared can be used as a reference for the detection of related materials of azacitidine, and is used for quality control applications of azacitidine and related preparations thereof.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07D 251/06 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
100.
MELPHALAN HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
The present invention relates to a melphalan hydrochloride crystal form, a preparation method therefor and an application thereof. The preparation method is convenient to operate, has a short reaction period, reduces environmental pollution caused by the three wastes because of using less organic solvent for reaction, and features mild and controllable reaction conditions, high yield of reaction products, and high purity. The prepared crystal form can be used for treating multiple myeloma, breast cancer, ovarian cancer, chronic lymphocytic and granulocytic leukemia, malignant lymphoma, multiple myeloma.
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
